Yellow fever

Journal of Clinical Virology

Volumn 64, Issue , 2015, Pages 160-173

  Monath, Thomas P ^a,b   Vasconcelos, Pedro F C ^c,d  

^a HOOKIPA BIOTECH AG   (Austria)

^b PaxVax Inc   (United States)

^c INSTITUTO EVANDRO CHAGAS   (Brazil)

^d UNIVERSIDADE DO ESTADO DO PARÁ   (Brazil)

Author keywords

Epidemiology; Pathogenesis; Yellow fever

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA INTERFERON; IMMUNOGLOBULIN M; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; YELLOW FEVER VACCINE;

ACUTE KIDNEY TUBULE NECROSIS; ADAPTIVE IMMUNITY; ALBUMINURIA; ANGOLA; ANURIA; APOPTOSIS; ARGENTINA; ARTICLE; BLEEDING TENDENCY; BRAZIL; BREEDING; BURKINA FASO; CAMEROON; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL AFRICAN REPUBLIC; CHAD; CLINICAL FEATURE; COLOMBIA; CONGO; COTE D'IVOIRE; CYTOTOXIC LYMPHOCYTE; DEFORESTATION; DEMOCRATIC REPUBLIC CONGO; DOWN REGULATION; DRUG MECHANISM; DRUG SAFETY; DRY SEASON; ECOTONE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; ETHIOPIA; FEVER; GABON; GAMBIA; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GHANA; GUINEA; HELPER CELL; HEMORRHAGIC FEVER; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MEMORY; INCIDENCE; INFECTION PREVENTION; INFLAMMATORY INFILTRATE; JAUNDICE; KIDNEY FAILURE; KUPFFER CELL; LIBERIA; LIVER CELL; LIVER INJURY; MALI; MASS IMMUNIZATION; MIGRATION; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NEUTROPHIL; NIGERIA; NONHUMAN; ORGANIC BRAIN SYNDROME; PARAGUAY; PATHOGENESIS; PERU; PLASMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAIN FOREST; REAL TIME POLYMERASE CHAIN REACTION; RIVER BASIN; SAVANNA; SEASON; SENEGAL; SENSITIVITY AND SPECIFICITY; SHOCK; SUDAN; TOGO; UGANDA; UREMIA; VECTOR CONTROL; VIRUS CONCENTRATION; VIRUS GENOME; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; YELLOW FEVER; AFRICA; ENDEMIC DISEASES; IMMUNOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; SOUTH AMERICA; TRAVEL; YELLOW FEVER VIRUS;

AFRICA; ENDEMIC DISEASES; HUMANS; INCIDENCE; SOUTH AMERICA; TRAVEL; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 84923578569     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.08.030     Document Type: Article

References (99)

1. Monath T.P., Gershman M., Staples E.J., Barrett A.D.T. Yellow fever vaccine. Vaccines 2012, 870-896. Saunders Elsevier, [chapter 36]. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
2. Vasconcelos P.F.C. Yellow fever in Brazil: thoughts and hypotheses on the emergence in previously free areas. Rev Saude Pública 2010, 44:1144-1149.
3. Barrett A.D., Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007, 52:209-229.
4. Jentes E.J., Poumerol G., Gershman M.D., et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011, 11:622-632.
5. World Health Organization Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Wkly Epidemiol Rec 2010, 85:465-472.
6. Souza R.P., Foster P.G., Sallum M.A., et al. Detection of a new yellow fever virus lineage within the South American genotype I in Brazil. J Med Virol 2010, 82:175-185.
7. Tuboi S.H., Costa Z.G.A., Vasconcelos P.F.C., Hatch D.L. Clinical and epidemiologic characteristics of yellow fever in Brazil: analysis of reported cases, 1998-2002. Trans R Soc Trop Med Hyg 2007, 101:169-175.
8. Monath T.P., Nichols R., Archambault W.T., et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002, 66:533-541.
9. Moreno E.S., Spinola R., Tengan C.H., et al. Yellow fever epizootics in non-human primates, São Paulo state, Brazil, 2008-2009. Rev Inst Med Trop Sao Paulo 2013, 55:45-50.
10. Bryant J.E., Holmes E.C., Barrett A.D. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog 2007, 3:e75.
11. Nájera P., Oliva O., Vilca L.M., Uriona S., Brathwaite O., Aldighieri S. YF risk mapping: methodology and results for the Americas. PAHO\HSD\IR viral diseases 2013, [unpublished information].
12. Goenaga S., Fabbri C., Dueñas J.C., Gardenal C.N., Rossi G.C., et al. Isolation of yellow fever virus from mosquitoes in Misiones province, Argentina. Vector Borne Zoonotic Dis 2012, 12:986-993.
13. Vasconcelos P.F.C., Bryant J.E., Travassos da Rosa A.P.A., et al. Genetic divergence and dispersal of yellow fever virus, Brazil. Emerg Infect Dis 2004, 10:1578-1584.
14. Vasconcelos P.F.C., Sperb A.F., Monteiro H.A.O., et al. Isolations of yellow fever virus from Haemagogus leucocelaenus in Rio Grande do Sul State, Brazil, in the Southern Cone. Trans R Soc Trop Med Hyg 2003, 97(1):60-62.
15. Almeida M.A.B., Cardoso J.A., Santos E., et al. Surveillance for yellow fever virus in non-human primates in Southern Brazil, 2001-2011: a tool for prioritizing human populations for vaccination. PLoS Negl Trop Dis 2014, 8(3):e2741. 10.1371/journal.pntd 0002741.
16. Cardoso J.C., Almeida M.A.B., Santos E., et al. Yellow fever virus isolation from Haemagogus leucocelaenus and Aedes serratus mosquitoes: southern Brazil, 2008. Emerg Infect Dis 2010, 16(12):1918-1924.
17. Romano A.P., Csta Z.A., Ramos D.G. Yellow fever outbreaks in unvaccinated populations, Brazil, 2008-2009. PLoS Negl Trop Dis 2014, 8(3):e2740. 10.1371/journal.pntd 0002740.
18. Markoff L. Yellow fever outbreak in Sudan. N Engl J Med 2013, 368:689-691.
19. Garske T., Van Kerkhove M.D., Yactayo S., et al. Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med 2014, 10.1371/journal.pmed.1001638.
20. Robertson S.E., Hull B.P., Tomori O., et al. Yellow fever: a decade of reemergence. JAMA 1996, 276(14):1157-1162.
21. World Health Organization. Epidemiology of yellow fever in the African region. WHO/OR-02 March 2012.
22. Monath T.P., Onejeme S., Okweke G., et al. Surveillance of yellow fever in Nigeria, 1970-1971. Nigerian Med J 1972, 21:178-186.
23. Bonney J.H.K., Osei-Kwasi M., Adiku T.K., et al. Hospital-based surveillance for viral hemorrhagic fevers and hepatitides in Ghana. PLoS Negl Dis 2013, 7(9):e2435. 10.1371/journal.pntd.0002435.
24. Beck A., Guzman H., Li L., et al. Phylogeographic reconstruction of African yellow fever virus isolates indicates recent simultaneous dispersal into East and West Africa. PLoS Negl Trop Dis 2013, 7(3):e1910. 10.1371/journal.pntd.0001910.
25. Germain M., Francy D.B., Monath T.P., et al. Yellow fever in the Gambia, 1978-1979: entomological aspects and epidemiological correlations. Am J Trop Med Hyg 1980, 29:929-940.
26. Sall A.A., Faye O., Diallo M., et al. Yellow fever exhibits slower evolutionary dynamics than dengue virus. J Virol 2010, 84:765-772.
27. Mutebi J.-P., Wang H., Li L., et al. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol 2001, 75:6999-7008.
28. Stock N.K., Laraway H., Faye O., et al. Biological and phylogenetic characteristics of yellow fever virus. Lineages from West Africa. J Virol 2013, 87:2895-2907.
29. Vasconcelos P.F.C., Costa Z.G., Travassos da Rosa E.S., et al. An epidemic of jungle yellow fever in Brazil, 2000. Implications of climatic alterations in disease spread. J Med Virol 2001, 65:598-604.
30. Mondet B., Travassos da Rosa A.P.A., Vasconcelos P.F.C. Les Risques D'Épidémisation Urbaine de la Fièvre Jaune au Brésil par les Vecteurs de la Dengue. Bull Soc Pathol Exot 1996, 89:107-114.
31. Kaufmann B., Rossmann M.G. Molecular mechanisms involved in the early steps of Flavivirus cell entry. Microbes Infect 2011, 13:1-9.
32. Perera R., Kuhn R.J. Structural proteomics of dengue virus. Curr Opin Microbiol 2010, 11:369-377.
33. Monath T.P., Barrett A.D.T. Pathogenesis and pathophysiology of yellow fever. Adv Virus Dis 2003, 60:343-395.
34. Quaresma J.A.S., Pagliari C., Medeiros D.B.A., et al. Immunity and immune response, pathology and pathologic changes. Progresses and challenges in the immunopathology of yellow fever. Rev Med Virol 2013, 23:305-331.
35. Theiler M. The virus. Yellow fever 1951, 46-136. McGraw-Hill, New York. G.K. Strode (Ed.).
36. Tesh R.B., Guzman H., Travassos da Rosa A.P.A., et al. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). 1. Virologic, biochemical and immunologic studies. J Infect Dis 2001, 183:1431-1436.
37. Quaresma J.A.S., Barros V.L.R.S., Fernandes E.R., et al. Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop 2005, 94:116-127.
38. Quaresma J.A.S., Barros V.L.R.S., Pagliari C., et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGFβ, TNFα and NK cells activity. Virology 2006, 345:22-30.
39. Quaresma J.A.S., Barros V.L.R.S., Pagliari C., et al. Immunohistochemical examination of the role of FAS ligand and lymphocytes in the pathogenesis of human liver yellow fever. Virus Res 2006, 116:91-97.
40. Quaresma J.A.S., Duarte M.I.S., Vasconcelos P.F.C. Midzonal lesion in the yellow fever: a specific pattern of liver injury caused by direct virus action and by immune anti-inflammatory response. Med Hypotheses 2006, 47:618-621.
41. Quaresma J.A.S., Barros V.L.R.S., Fernandes E.R., et al. Hepatocyte lesions and cellular immune response in yellow fever infection. Trans R Soc Trop Med Hyg 2007, 101:161-168.
42. Theiler M., Anderson C.R. The relative resistance of dengue immune monkeys to yellow fever virus. Am J Trop Med Hyg 1975, 24:115-117.
43. Xiao S.Y., Guzman H., da Rosa A.P., et al. Alteration of clinical outcome and histopathology of yellow fever virus infection in a hamster model by previous infection with heterologous flaviviruses. Am J Trop Med Hyg 2003, 68:695-703.
44. Monath T.P., Brinker K.R., Chandler F.W., et al. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations in the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg 1981, 30:431-436.
45. ter Meulen J., Sakho M., Koulemou K., et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 2004, 190(10):1821-1827.
46. Li G., Duan T., Tesh R.B., et al. Yellow fever virus infection in Syrian golden hamsters: relationship between cytokine expression and pathologic changes. Int J Clin Exp Pathol 2008, 1:169-179.
47. Triviño N.H., Montaña D., Castellanos J.E. Dengue-yellow fever sera cross-reactivity. Challenges for diagnosis. Rev Saude Pública 2008, 10:299-307.
48. Weidmann M., Faye O.U.S., Faye O.U.M., et al. Improved DNA probe based assay for the detection of African and South-American yellow fever virus strains. J Clin Virol 2010, 48:187-192.
49. Domingo C., Patel P., Yillah J., et al. Advanced yellow fever virus genome detection in point-of-care facilities and reference laboratories. J Clin Microbiol 2012, 50:4054-4060.
50. Nunes M.R.T., Palacios G., Nunes K.N.B., et al. Evaluation of two molecular methods for the detection of yellow fever virus genome. J Virol Methods 2011, 174:29-34.
51. Kwallah A.O., Inoue S., Muigai A.W., et al. A real-time reverse transcription loop-mediated isothermal amplification assay for the rapid detection of yellow fever virus. J Virol Methods 2013, pii: S0166-0934(13)00184-5. 10.1016/j.jviromet.2013.05.004.
52. Escadafal C., Faye O., Sall A.A., et al. Rapid molecular assays for the detection of yellow fever virus in low-resource settings. PLoS Negl Trop Dis 2014, 8(3):e2730. 10.1371/journal.pntd.0002730.
53. World Health Organization WHO Working Group on technical specifications for manufacture and evaluation of yellow fever vaccines, Geneva, Switzerland, 13-14 May 2009. Vaccine 2010, 28:8236-8245.
54. Lindsey N.P., Schroeder B.A., Miller E.R., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26:6077-6082.
55. Khromava A.Y., Eidex R.B., Weld L.H., et al. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
56. Monath T.P., Liu J., Kanesa-Thasan N., et al. A live, attenuated recombinant vaccine against West Nile virus. Proc Natl Acad Sci USA 2006, 103:6694-6699.
57. Domingo C., Yactayo S., Agbenu E., et al. Detection of yellow fever 17D genome in urine. J Clin Microbiol 2011, 49:760-762.
58. Lamson D.M., Ramani R., Kleabonas M., et al. An unusual case of influenza-like illness after yellow fever vaccination. J Clin Virol 2014, 60:67-69.
59. Roukens A.H., Vossen A.C., Bredenbeek P.J., et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 2008, 3(4):e1993.
60. Vratskikh O., Stiasny K., Zlatkovic J., et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog 2013, 9(June (6)):e1003458.
61. Mason R.A., Tauraso N.M., Spertzel R.O., Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973, 25:539-544.
62. Julander J.G., Trent D.W., Monath T.P. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine 2011, 29:6008-6016.
63. Hepburn M.J., Kortepeter M.G., Pittman P.R., et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. Vaccine 2006, 24:2843-2849.
64. Neves P.C., Matos D.C., Marcovistz R., Galler R. TLR expression and NK cell activation after human yellow fever vaccination. Vaccine 2009, 27:5543-5549.
65. Kohler S., Bethke N., Böthe M., et al. The early cellular signatures of protective immunity induced by live viral vaccination. Eur J Immunol 2012, 42:2363-2373.
66. Querec T.D., Akondy R.S., Lee E.K., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Rev Immunol 2009, 10:116-125.
67. Gaucher D., Therrien R., Kettaf N., et al. Yellow fever induces integrated multilineage and polyfunctional immune responses. J Exp Med 2009, 205:3119-3131.
68. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 2009, 9:741-747.
69. Silva M.L., Martins M.A., Espirito-Santo L.R., et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 2011, 29:583-592.
70. Gotuzzo E., Yactayo S., Cordova E. Review article efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 2013, 89:434-444.
71. Belmusto-Worn V.E., Sanchez J.L., McCarthy K., et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YELLOW FEVER-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005, 72:189-197.
72. Miller J.D., van der Most R.G., Akondy R.S., et al. Human effector and memory CD8+ responses to smallpox and yellow fever vaccines. Immunity 2008, 28:710-722.
73. Akondy R.S., Monson N.D., Miller J.D., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009, 183:7919-7930.
74. Vasconcelos P.F., Luna E.J., Galler R., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358:91-97.
75. Martin M., Tsai T.F., Cropp B., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358:98-104.
76. Chan R.C., Penney D.J., Little D., et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358:121-122.
77. Monath T.P. Short report: suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg 2010, 82:919-921.
78. Gershman M.D., Staples J.E., Bentsi-Enchill A.D., et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012, 30:5038-5058.
79. Monath T.P. Review of the risks and benefits of yellow fever vaccination including some new analyses. Expert Rev Vaccines 2012, 11:427-448.
80. Seligman S.J. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis 2011, 17:1891-1893.
81. Roukens A.H., Soonwala D., Joosten S.A., et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE 2011, 6(12):e27753.
82. Belsher J.L., Gay P., Brinton M., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25:8480-8485.
83. Bigham A.W., Buckingham K.J., Husain S., et al. Host genetic risk factors for West Nile virus infection and disease progression. PLoS ONE 2011, 6(9):e24745.
84. Pulendran B., Miller J., Querec T.D., et al. Case of yellow-fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008, 198:500-507.
85. McMahon A.W., Eidex R.B., Marfin A.A., et al. Neurologic disease associated with 17D-204 fever vaccination: a report of 15 cases. Vaccine 2007, 25:1727-1734.
86. Glass W.G., McDermott D.H., Lim J.K., et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203:35-40.
87. World Health Organization. Detection and investigation of serious adverse events following yellow fever vaccination: guidance from an informal consultation of experts, 18-19 November.
88. http://www.france24.com/en/20130706-interview-malcolm-brabant-bbc-correspondent-yellow-fever-vaccination-psychotic-episodes.
89. Traiber C., Coelho-Amaral P., Ritter V.R., Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. J Pediatr (Rio J) 2011, 87:269-272.
90. Kuhn S., Twele-Montecinos L., MacDonald J., et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. Can Med Assoc J 2011, 183:E243-E245.
91. Monath T.P. Treatment of yellow fever. Antiviral Res 2008, 78:116-124.
92. Julander J.G., Ennis J., Turner J., Morrey J.D. Treatment of yellow fever virus with an adenovirus-vectored interferon DEF201, in a hamster model. Antimicrob Agents Chemother 2011, 55:2067-2073.
93. Sbrana E., Xiao S.Y., Guzman H., et al. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am J Trop Med Hyg 2004, 71:306-312.
94. Vellozzi C., Mitchell T., Miller E., et al. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004. Am J Trop Med Hyg 2006, 75:333-336.
95. ter Meulen J., Sakho M., Koulemou K., et al. Activation of the cytokine network and unfavourable outcome in patients with yellow fever. J Infect Dis 2004, 190:1821-1827.
96. Monath T.P., Fowler E., Johnson C.T., et al. A clinical trial of an inactivated, cell culture vaccine against yellow fever. N Engl J Med 2011, 364:1326-1333.
97. Wiysonge C.S., Nomo E., Mawo J., et al. Yellow fever control in Cameroon: where are we now and where are we going?. BMC Med 2008, 6:3-7.
98. Briand S., Beresniak A., Nguyen T., et al. Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLoS Negl Trop Dis 2009, 3(7):e483. 10.1371/journal.pntd.0000483.
99. Breugelmans J.G., Lewis R.F., Agbenu E., et al. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. Vaccine 2013, 31:1819-1829.